Dr Reddy’s Laboratories shares gain on generic Zenatane launch

Dr Reddy's gains after company said it launched a generic version of Accutane drug.

Written by Reuters | Published: April 1, 2013 10:30:03 am

Shares in Dr Reddy’s Laboratories Ltd gain 2.1 percent after the company on Thursday said in a statement that it launched Zenatane,a generic version of Accutane drug,following its approval by the United States Food & Drug Administration (USFDA).

* The company added that the drug had $309 million in sales for the most recent twelve months ending January 2013,according to IMS Health.

* “Assuming an incremental 20-25 percent price drop and 20 percent market share,this could be $50 million per year revenue opportunity for Dr.Reddy’s,” Morgan Stanley said in a report.

For all the latest News Archive News, download Indian Express App